Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2004 / Article

Special Article | Open Access

Volume 18 |Article ID 748749 | https://doi.org/10.1155/2004/748749

Jenny Heathcote, "Clinical Trials in Chronic Liver Disease - What Do They Achieve?", Canadian Journal of Gastroenterology and Hepatology, vol. 18, Article ID 748749, 4 pages, 2004. https://doi.org/10.1155/2004/748749

Clinical Trials in Chronic Liver Disease - What Do They Achieve?

Received08 Jun 2004
Accepted08 Jun 2004

Abstract

The past 30 years have seen rapid growth in the number of clinical trials in liver disease; due mostly to effective drug discovery programs by the pharmaceutical industry. The advantages associated with therapeutic trials in chronic liver disease, or any other disease for that matter, go far beyond potential benefit to the individual patient, other beneficiaries include the treating physician, the sponsoring agency and their investors, the institution/university and the general public. But there is always a downside to any experiment. The disadvantages and advantages of clinical trials in liver disease are the topics for this discussion.

Copyright © 2004 Canadian Association of Gastroenterology. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution, and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views51
Downloads137
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.